Key points are not available for this paper at this time.
Abstract:: Nanotechnology has emerged as a promising frontier in the field of drug delivery, offering unprecedented opportunities for precise and targeted interventions in neurodegenerative disorders, such as Parkinson's and Alzheimer's diseases. This review explores recent advancements in nanotechnology-based delivery systems designed to enhance drug transport across the blood-brain barrier and facilitate targeted drug delivery to the central nervous system. The unique challenges posed by the intricate central nervous system architecture, particularly in the context of Parkinson's and Alzheimer's diseases, necessitate innovative solutions to improve therapeutic outcomes. The review comprehensively discusses various nanocarrier platforms, including liposomes, polymeric nanoparticles, dendrimers, and exosomes, and their potential applications in drug delivery to the central nervous system (CNS). Special emphasis is placed on addressing the multifaceted challenges associated with neurodegenerative diseases, such as the need for sustained drug release, protection of therapeutic agents from enzymatic degradation, and the efficient crossing of the blood-brain barrier. Furthermore, the review highlights recent breakthroughs in nanotechnology-driven diagnostic and therapeutic approaches, ranging from early detection of disease biomarkers to the targeted delivery of neuroprotective agents. The potential of personalized medicine and the integration of advanced imaging techniques with nanotechnology for precise disease monitoring are also discussed. In conclusion, this review provides a comprehensive overview of recent advancements in nanotechnologybased delivery systems tailored for CNS targeting, with a specific focus on Parkinson's and Alzheimer's diseases. The synthesis of current research findings underscores the transformative potential of nanotechnology in reshaping the landscape of therapeutic strategies for neurodegenerative disorders, offering hope for improved patient outcomes and the development of novel treatment modalities.
Ahmad et al. (Tue,) studied this question.